First US mRNA flu vaccine signals a new era for vaccines
FDA approves mFLUSIVA, the United States’ first mRNA influenza vaccine, marking a milestone for the platform after a year of funding reversals; unlike egg-based vaccines, it can be updated in two to three months and deployed closer to flu season, hinting at future breakthroughs across vaccines and therapies, though real-world uptake will depend on access, cost, and regulatory guidance.